Brookline Capital Management Predicts MRKR Q1 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR – Free Report) – Investment analysts at Brookline Capital Management issued their Q1 2025 earnings per share estimates for Marker Therapeutics in a report released on Monday, March 31st. Brookline Capital Management analyst L. Cann anticipates that the company will earn ($0.66) per share for the quarter. Brookline Capital Management has […]